生物医药企业从基础研发到成果转化的过程中,常常要经历两个被称之为“死亡谷”的曲折阶段成熟生物医药企业在融资市场上的强势表现,已经开始让不少大拿变得谨慎起来。某PE曾经接触过一家成熟的生物医药企业,对方直接报出100倍的PE,该公司参考的依据是依照已经上市企业的PE价格,这个可以被称为天价的 Biomedical companies from basic research and development to the transformation of the results of the process, they often have to go through two known as the “Death Valley” tortuous stages of mature biomedical companies in the financing market, a strong performance, has begun to let a lot of Canadian Be cautious. A PE has been exposed to a mature biopharmaceutical company, the other directly reported 100 times the PE, the company’s reference is based on already listed companies PE prices, which can be called the high price